FDA rejects Biohaven treatment for Lou Gehrig ’s disease

Biohaven Pharmaceutical Holding Co. has reported that its new treatment for armyotrophic lateral sclerosis, or Lou Gehrig ’s disease, has failed to win FDA approval.

Source: PharmaManufacturing.com - July 22, 2019 Category: Pharmaceuticals Source Type: news